As part of its ongoing commitment to strengthening national drug security, Mubadala Bio has announced the introduction of eight new essential medicines in the UAE through its subsidiaries. This milestone underscores the company’s mission to enhance healthcare outcomes for patients across the UAE and the wider region.
The initiative marks significant progress in advancing the UAE’s goal to establish itself as a regional hub for life sciences, reinforcing drug security, improving access to vital medicines, and driving a sustainable, knowledge-based economy. The newly introduced medicines include high-demand therapies widely used in hospitals, clinics, and by patients nationwide:
• Rivaroxaban – an anticoagulant used to prevent blood clots in the brain and other blood vessels in the body
• Linezolid – an essential antibiotic for treating drug-resistant bacterial infections
• Sugammadex – used for anesthesia recovery following surgery
• Fluconazole – an antifungal for serious fungal infections
• Pantoprazole – injectable form of the product used to reduce stomach acid
• Ondansetron – injectable form of the product used to prevent nausea and vomiting mainly from cancer treatment
• Bupivacaine – a long-acting local anesthetic for pain control
• Sodium Chloride Inhalation Solution – used to clear airways and to clear mucus in the lungs
These medications are now locally manufactured at Mubadala Bio’s UAE facilities — Gulf Inject, Wellpharma, and Bioventure Healthcare — addressing growing demand while ensuring a reliable, uninterrupted supply of critical therapies within the nation.
Dr. Bakheet Al Katheeri, CEO of Mubadala’s UAE Investments Platform and Chairman of Mubadala Bio, said, “As a national champion, Mubadala Bio was launched to strengthen the UAE’s life sciences sector and to enable local production of essential medications. With the launch of these products, Mubadala Bio is delivering on this commitment, and is ensuring a continuous and reliable supply of key medical therapies locally.”
Commenting on the milestone, Dr. Essam Mohamed, CEO of Mubadala Bio, said, “We are pleased to introduce new locally produced medications that support healthcare providers and patients across the UAE. These steps reflect our long-term commitment to strengthening the country’s life sciences sector and expanding capabilities in local manufacturing.”
Hamad Husein Almarzooqi, Deputy CEO of Mubadala Bio, added, “With these launches, we’re proving that Mubadala Bio is not only meeting today’s needs but is also shaping the future of the life sciences industry in the UAE and the region. Mubadala Bio is dedicated to delivering transformative health outcomes and is committed to becoming a global leader in our sector.”
Mubadala Bio currently owns and operates 10 pharmaceutical assets across Asia, Africa, and Europe, including six in the UAE. With capabilities spanning tablets, capsules, small and large-volume injectables, and ophthalmic and otic solutions, the company manufactures and distributes over 10,000 products to more than 100 countries worldwide.
(Inputs from WAM)
